# BridgeBio Oncology Therapeutics, Inc.: Form SCHEDULE 13D, filed Aug 18, 2025

- Company: [BridgeBio Oncology Therapeutics, Inc.](/companies/bbot.md) (CIK 1869105)
- Form: SCHEDULE 13D
- Filed: 2025-08-18
- Accepted by EDGAR: Aug 18, 2025, 17:41 ET
- Period: not reported
- Accession: 0001193125-25-182790
- Inline XBRL: no
- Main document: https://www.sec.gov/Archives/edgar/data/1869105/000119312525182790/xslSCHEDULE_13D_X01/primary_doc.xml
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1869105/000119312525182790/

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1869105/000119312525182790/xslSCHEDULE_13D_X01/primary_doc.xml

Filed Aug 18, 2025.
Source: SEC EDGAR, the filing index for accession 0001193125-25-182790. Last ingested by Listed: Nov 5, 2026, 16:25 ET. No prices; not investment advice.